Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the french adjuvant study group 08 trial - Fargeot, P; Bonneterre, J; Roche, H (J Clin Oncol, 2004)
et al.